Crinetics Pharmaceuticals (CRNX) Competitors $29.88 +0.44 (+1.48%) Closing price 07/3/2025 01:45 PM EasternExtended Trading$30.20 +0.32 (+1.07%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CRNX vs. QGEN, MRNA, ASND, VTRS, BPMC, BBIO, VRNA, ROIV, ELAN, and RVMDShould you be buying Crinetics Pharmaceuticals stock or one of its competitors? The main competitors of Crinetics Pharmaceuticals include Qiagen (QGEN), Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Crinetics Pharmaceuticals vs. Its Competitors Qiagen Moderna Ascendis Pharma A/S Viatris Blueprint Medicines BridgeBio Pharma Verona Pharma PLC American Depositary Share Roivant Sciences Elanco Animal Health Revolution Medicines Crinetics Pharmaceuticals (NASDAQ:CRNX) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability. Do insiders and institutionals have more ownership in CRNX or QGEN? 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 4.6% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor CRNX or QGEN? In the previous week, Qiagen had 3 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 5 mentions for Qiagen and 2 mentions for Crinetics Pharmaceuticals. Qiagen's average media sentiment score of 0.75 beat Crinetics Pharmaceuticals' score of 0.22 indicating that Qiagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Qiagen 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, CRNX or QGEN? Crinetics Pharmaceuticals has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Do analysts rate CRNX or QGEN? Crinetics Pharmaceuticals presently has a consensus target price of $71.75, suggesting a potential upside of 140.17%. Qiagen has a consensus target price of $49.40, suggesting a potential upside of 2.19%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Crinetics Pharmaceuticals is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Crinetics Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Qiagen 0 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.30 Is CRNX or QGEN more profitable? Qiagen has a net margin of 4.68% compared to Crinetics Pharmaceuticals' net margin of 0.00%. Qiagen's return on equity of 14.61% beat Crinetics Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Crinetics PharmaceuticalsN/A -30.95% -28.12% Qiagen 4.68%14.61%8.80% Which has stronger earnings & valuation, CRNX or QGEN? Qiagen has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCrinetics Pharmaceuticals$1.04M2,689.61-$298.41M-$3.82-7.82Qiagen$1.98B5.43$83.59M$0.40120.85 SummaryQiagen beats Crinetics Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRNX vs. The Competition Export to ExcelMetricCrinetics PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.79B$2.43B$5.53B$9.05BDividend YieldN/A1.78%5.24%4.02%P/E Ratio-7.829.1027.5120.24Price / Sales2,689.61682.84416.89118.64Price / CashN/A158.5936.8958.07Price / Book2.094.588.035.67Net Income-$298.41M$31.34M$3.18B$249.13M7 Day Performance-0.28%3.25%2.90%3.28%1 Month Performance-7.56%7.08%3.71%5.56%1 Year Performance-31.84%0.17%36.03%21.13% Crinetics Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRNXCrinetics Pharmaceuticals3.5658 of 5 stars$29.88+1.5%$71.75+140.2%-32.4%$2.79B$1.04M-7.82210QGENQiagen4.0446 of 5 stars$48.07+0.6%$49.40+2.8%+22.5%$10.69B$1.98B120.525,765Dividend AnnouncementMRNAModerna4.3787 of 5 stars$27.59+1.6%$46.61+68.9%-73.7%$10.67B$3.24B-3.165,800Options VolumeASNDAscendis Pharma A/S3.6652 of 5 stars$172.60+0.2%$220.67+27.8%+29.7%$10.55B$393.54M-27.481,017News CoverageAnalyst ForecastVTRSViatris3.306 of 5 stars$8.93-0.9%$10.40+16.5%-10.9%$10.48B$14.74B-2.8232,000BPMCBlueprint Medicines1.5713 of 5 stars$128.18+0.1%$128.06-0.1%+17.6%$8.28B$562.12M-51.89640BBIOBridgeBio Pharma4.7073 of 5 stars$43.18-3.7%$58.85+36.3%+74.8%$8.20B$221.90M-12.23400News CoverageInsider TradeAnalyst RevisionHigh Trading VolumeVRNAVerona Pharma PLC American Depositary Share2.6145 of 5 stars$94.58+0.8%$101.10+6.9%+480.4%$8.05B$42.28M-47.2930Positive NewsAnalyst ForecastROIVRoivant Sciences1.5551 of 5 stars$11.27-1.1%$17.50+55.3%+3.5%$7.66B$29.05M-45.08860ELANElanco Animal Health2.2359 of 5 stars$14.29flat$15.17+6.1%+3.6%$7.10B$4.44B19.319,000News CoverageAnalyst ForecastRVMDRevolution Medicines4.589 of 5 stars$36.79-0.3%$67.58+83.7%+0.2%$6.85B$11.58M-9.20250Analyst Revision Related Companies and Tools Related Companies Qiagen Competitors Moderna Competitors Ascendis Pharma A/S Competitors Viatris Competitors Blueprint Medicines Competitors BridgeBio Pharma Competitors Verona Pharma PLC American Depositary Share Competitors Roivant Sciences Competitors Elanco Animal Health Competitors Revolution Medicines Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRNX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRNX Stock Alerts